| 产品描述: | Camizestrant (AZD-9833) 是一种有效的口服活性雌激素受体 (ER) 拮抗剂。Camizestrant 可以用于 ER+ HER2-乳腺癌的相关研究。 |
| 靶点: |
IC50: estrogen receptor (ER);EstrogenReceptor/ERR |
| 体外研究: |
Camizestrant is extracted from patent US20180111931A1, example 17. |
| 体内研究: |
Camizestrant (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft. Camizestrant (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice . |
| 参考文献: |
1.Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.099 ml |
10.493 ml |
20.986 ml |
| 5 mM |
0.42 ml |
2.099 ml |
4.197 ml |
| 10 mM |
0.21 ml |
1.049 ml |
2.099 ml |
| 50 mM |
0.042 ml |
0.21 ml |
0.42 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |